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OBJECTIVES: To examine the association between teriparatide adherence and
health care utilization and costs in “real world” U.S. hip fracture (HFx) patients.
METHODS: A large U.S. administrative claims database was used to identify pa-
tients aged 50 with an HFx between January 1, 2002-December 31, 2010 (first
observed HFx HFx index). All patients included had 6months of pre-HFx index
continuous enrollment (baseline) and no baseline teriparatide, cancer, or Paget’s
disease. Patients initiating teriparatide post-HFx index were followed from initia-
tion (exposed period) until censoring at switch to bisphosphonates, disenrollment,
36 months post-HFx index, cancer, or Paget’s disease. Adherence was measured as
the proportion of days covered (PDC) by teriparatide during the exposed period
(teriparatide PDC). Outcomes were repeated HFx and per-patient per-month (PPPM)
inpatient costs and number of inpatient admissions, outpatient costs, pharmacy
costs, and total costs. Multivariable Generalized Linear Models examined the asso-
ciation between teriparatide PDC (0.5 ‘low,’ 0.5-0.8 ‘medium,’ 0.8 ‘high’) and
the outcomes, adjusting for important patient characteristics. RESULTS: Study
included 824 patients; mean age 75 years, 90% female; 29% low PDC; 27% medium
PDC; 44% high PDC. In multivariable analyses, high adherence was significantly (all
P0.05) associated with increased PPPM pharmacy costs (low$621; medi-
um$1,093; high$1,572), but the lowest PPPM inpatient costs (low$963; me-
dium$960; high$629), number of inpatient admissions (incidence rate ratio vs.
high1.26 [low] and 1.28 [medium]), and outpatient costs (low$1087; medi-
um$1068; high$776). PPPM total costs differed significantly across the teripa-
ratide PDC groups (all P0.05) and were highest in the medium PDC group
(low$2599; medium$3163; high$2869). Too few repeated hip fractures
(low11; medium6; high2) occurred to complete multivariable analysis.
CONCLUSIONS:Among HFx patients newly-initiating teriparatide, significantly in-
creased pharmacy costs associated with greater teriparatide adherence were offset
by significantly lower inpatient admissions as well as inpatient and outpatient
costs.
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OBJECTIVES: Neuropathic pain (NeP) is a chronic condition endured by those who
have suffered damage to their somatosensory system. This damage can often re-
sult from various concomitant diseases. The condition can have a severe effect on
the level of quality of life (QoL). The purpose of this abstract is to investigate the
level of pain and impact on QoL of patients who suffer from NeP relative to recorded
pain levels. METHODS: Data were drawn from the 2012 Adelphi NeP Disease Spe-
cific Programme, a cross sectional survey involving 121 primary care physicians
and 292 specialists across France, Germany, Italy, Spain and UK. Physicians pro-
vided data on diagnosis and treatment patients, patients filled a self-completion
questionnaire which included the EQ-5D and Brief Pain Inventory questionnaires
(BPI; Interference measure). Patients were split into those who have peripheral
(N2033), central (N301) or both peripheral and central (P&C) condition(s)
(N165) and by categorising patients by peripheral conditions causing NeP.
RESULTS: A total of 3956 patients were included, of whom 2499 completed both
EQ5D and BPI. For patients suffering with, peripheral, central and P&C, BPI values
were 4.34, 4.70 and 4.77 respectively whereas EQ5D values were 0.591, 0.535 and
0.486 respectively. All differences between peripheral, central and P&C were sta-
tistically significant (P0.01). Average scores across the entire sample were EQ-5D
0.577, BPI 4.41. Certain conditions were associated with lower QoL and greater pain,
notably radiculopathy (N472, EQ-5D 0.553, BPI 4.66), fibromyalgia (N189, EQ-5D
0.514, BPI 5.06) and alcoholism (N84, EQ-5D 0.544, BPI 4.93) all p0.01 compared to
population means. CONCLUSIONS: These data show an inverse relationship be-
tween level of pain and the QoL experienced by patients using the EQ-5D and BPI.
This was particularly evident amongst patients with P&C and within NeP caused by
radiculopathy, fibromyalgia and alcoholism. Better pain control would therefore
lead to improvements in QoL.
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OBJECTIVES: The HS-FOCUS questionnaire was used to monitor patient reported
outcomes for mucopolysaccharidosis II (MPS II, Hunter Syndrome) patients. Pre-
liminary item analysis suggested that some of the items were redundant and/or
not informative. The objective of this study was to shorten HS-FOCUS without
compromising the psychometric properties of the original patient and parent ver-
sions while reducing the respondent’s burden. METHODS: Data collected in a ran-
domized trial were used. Final items were selected based on their content validity,
per clinicians’ input and by item performance as described below. Reliability, va-
lidity, and ability to detect change were assessed in the shortened version of the
HS-FOCUS. RESULTS: Forty-nine patients above 12 years old and 84 parents com-
pleted the HS-FOCUS. Items were removed owing to ambiguous wordings, floor
effects ( 60%), high inter-item correlations ( 0.90) and inadequate content or
clinical relevance. The Sleeping domain was removed from both the shortened
patient (32 items) and parent versions (35 items), which kept 5 functional domains.
The internal consistency and test-retest reliability were 0.70 for all domains ex-
cept the Breathing domain in patients. The test-retest reliability was assessed
using responses at Baseline and Week 18 and was 0.70 for all domains except the
Schooling/Work for parents’ version. Significant correlation (0.30) with similar
concepts of other instruments and the 6-Minute-Walk test demonstrated concur-
rent validity. Scores were significantly different in all domains among levels of
disability as measured by CHAQ disability score (CHAQ-DIS). Changes in domain
scores were responsive to changes in patients’ health status also measured by the
CHAQ-DIS. CONCLUSIONS: The shortened HS-FOCUS will reduce patient and par-
ent burden without compromising its measurement properties. The shortened
HS-FOCUS is a reliable and valid instrument for use in clinical trials or registries,
with increased ability to detect change compared to the original version.
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OBJECTIVES: ZQOL is the first and largest UK-wide cross-sectional study to explore
burden associated with HZ and PHN. Findings have previously highlighted that HZ
and PHN are painful conditions that significantly impact patients’ lives. However,
only limited real-world research exploring the presentation of HZ and PHN and the
patient-reported and economic impact of HZ and PHN has been conducted.
METHODS: The UK ZQOL study comprised 229 HZ and 152 PHN patients over the
age of 50. Patients completed validated patient-reported outcome measures and a
study-specific questionnaire exploring HZ and PHN presentation and patient-re-
ported impact. Recruiting doctors provided information regarding patients’ disease
presentation and medical resource use. RESULTS: Results indicate that HZ patients
experience a range of non-pain/non-rash symptoms prior to and following the
onset of the HZ rash, including sleep disturbance (50.2%), headaches (31.4%) and
nausea (27.9%), and that these persist in PHN patients. Both HZ and PHN patients
presented with pain, rash or numbness primarily on the torso (HZ-59%; PHN-66%)
or head/neck (HZ-30%; PHN-49%). 62.0% of HZ patients presented within a week of
experiencing pain where their shingles rash appeared. PHN patients experienced
pain for an average of 3.5 years; 25% experienced numbness. Doctors report pre-
scribing multiple medications for HZ (e.g. analgesics (71.2%) and antivirals (69.4%))
and PHN (e.g. antidepressants (59.2%) and level 1 analgesics (55.3%)). While fre-
quency of consultations, referrals or emergency care is low among HZ patients
(3.5%),PHN patients saw their doctor an average of 9.5 times; 14.5% received refer-
rals - contributing further to direct costs. Indirect costs for HZ and PHN manifest in
significant time lost from normal activities, including taking time off work (82.1%).
CONCLUSIONS: ZQOL study findings provide important ‘real-world’ information
regarding the presentation of HZ and PHN and highlight unmet needs that contrib-
ute to both patient-reported and economic burden in these populations.
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OBJECTIVES: To identify those symptoms and impacts with chronic low back pain
(cLBP) considered by patients to be the most bothersome for the purpose of iden-
tifying relevant concepts to assess in a new patient-reported outcome (PRO) mea-
sure for cLBP. METHODS: Adults (18-80 years) with clinical diagnosis of cLBP of
non-malignant origin present for at least 3 months and a current pain score 4 on
a 0-10 numerical rating scale (NRS) were recruited from 5 U.S. clinical sites and
Germany. Forty-three individual qualitative patient interviews were conducted
using a semi-structured interview guide designed to elicit relevant symptoms and
impacts. At the close of the qualitative interviews, patients rated their most both-
ersome symptoms and most difficult impacts using a 0-10 numerical rating scale
(NRS). Rating results (mean SD) were summarized for all symptoms and impacts
using descriptive statistics. RESULTS: Participant mean age was 48.613.0, major-
ity were female (53.5%) and 74.4% of participants described their racial/ethnic
group as White/Caucasian (Non-Hispanic). Mean pain intensity was 6.71.3. Pa-
tients rated most number of symptoms they had reported as being highly bother-
some on the NRS, with the highest ratings observed for - excruciating pain
(9.60.8); sharp pain (8.71.3); shooting pain (8.61.6); electric shocks/jolts
(8.02.0); spasms (7.72.7); cramping (7.52.4); burning pain (7.42.1); throbbing
pain (7.02.4); radiating pain (6.92.8); aching pain (6.92.5); and pins and needles
(6.71.6). The highest impact difficulty ratings included difficulty with: stairs
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(9.51.0); standing (8.41.8); sleep (7.92.3); work-related activities (7.92.4); walk-
ing (7.82.2); sexual activity (7.71.7); emotions (7.72.4); lifting (7.62.5); sitting
(7.52.0); social activities (7.22.4); and traveling (6.82.2). CONCLUSIONS: Quali-
tative interviews identified a wide-variety of bothersome symptoms and impacts
experienced by patients with cLBP. Patient-reported outcome instruments should
measure those experiences, which reflect concepts most relevant to patients. Ad-
ditional work is needed to assess whether items measuring these concepts are
sensitive to change with treatment.
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OBJECTIVES: The primary objective was to examine the effect of 8% capsaicin
patch on change in “usual pain” using a PNRS (Pain Numeric Rating Scale) from
baseline to end of treatment. A secondary objective was to examine utility scores
assessed by the EQ-5D. METHODS: Adult patients (n211) diagnosed with periph-
eral neuropathic pain (excluding diabetes polyneuropathy) were included. The fol-
lowing parameters were investigated over a 12 week follow up period after a single
application: - Pain Numeric Rating Scale (PNRS, 0-10) to assess average pain inten-
sity over the last 24 hours, i.e., “usual pain” - EQ-5D - Size of treated area. RESULTS:
A total of 196 patients completed the study, 66% women and 34% men. Mean age
was 54.2 years (range 18-87). At baseline, the “usual pain” intensity was 6.3 (SD 1.8).
The mean change of PNRS from baseline to 14 - 90 days post treatment (average
pain reduction) was -0.90 (SD 2.08), p  0.001. Maximum mean reduction of “usual
pain” at any time point was -1.77 (SD 2.36), p 0.001. Mean EQ-5D health score was
0.29 (SD 0.31) at baseline (range -0.38-1.00). During the post-treatment period the
change was 0.26 (SD 0.30), p  0.001. At baseline, 66% of all patients reported
“Extreme Problem” in the pain/discomfort dimension and corresponding figures
for the post-treatment period was 43%. Median area treated was estimated to 179
cm2(range 3-1120) corresponding to 1.3 patches used per patient per treatment.
CONCLUSIONS: In this population of patients with peripheral neuropathic pain
and a markedly reduced QoL, a single treatment of capsaicin 8% significantly re-
duced patients’ experience of “usual pain” and improved short-term QoL evaluated
by EQ-5D.
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OBJECTIVES: Review the development and properties of PRO instruments used in
clinical trials and observational studies of patients with SLE. METHODS: A struc-
tured search was conducted to identify published articles in 2005-2011 through key
literature databases (EMBASE and MEDLINE/PUBMED). Conference abstracts from
targeted rheumatology, outcomes research and quality-of-life (QOL) scientific
meetings in 2009-2011 were included. SLE therapy clinical trials within the past five
years were identified through the ClinicalTrials.gov database. RESULTS: Over 60
different PRO instruments were used in SLE-related research; 7 were lupus specific,
11 assessed general QoL and the rest assessed select (diverse) disease symptoms
(e.g., fatigue, pain) or other patient attributes (e.g., satisfaction, adherence). The
SF-36, LupusQoL, and LupusPRO were most frequently used in SLE research. These
instruments have 36, 34, and 43 items, respectively. All three instruments have a
recall period of past four weeks; they demonstrated robust reliability and construct
validity when used in SLE patient samples, but generally weak associations
(r0.12-0.29) with SLE disease-activity indices. Validated symptom-specific FACIT-
Fatigue scale was also used in some studies to measure this important aspect of
patient experience and it correlated with SLE disease-activity indices. Recently, 10
items from the LupusPRO were validated for use as ‘Lupus Impact Tracker’ (LIT) to
retain the reliability and validity of the longer tool while decreasing questionnaire
burden. Brief validated instruments used in rheumatic-diseases (e.g., RAPID3: 15
items) are also being studied in SLE. CONCLUSIONS: The SF-36, LupusQoL, and
LupusPRO are the most widely used validated PRO instruments, but these have a
varying degree of questionnaire burden and specificity to SLE symptoms. Shorter
versions of validated PROs (e.g., SF-12, LIT) or instruments such as RAPID3 may
minimize questionnaire burden. The practicality of these PRO instruments for use
in daily practice to discriminate clinically meaningful changes in patient-reported
SLE treatment outcomes deserves further investigation.
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OBJECTIVES: To identify symptoms and impacts associated with chronic low back
pain (cLBP) that patients report spontaneously and in response to probes during
concept elicitation interviews.METHODS:Adult patients (18-80 years) with clinical
diagnosis of cLBP of non-malignant origin present for at least 3 months with a
current pain score 4 on a 0-10 numerical rating scale (NRS) were recruited from
U.S. and Germany sites. In order to explore relevance of concepts to patients,
trained qualitative interviewers conducted semi-structured individual interviews,
using open-ended questions to elicit spontaneous reports of symptom/impact con-
cepts, followed by probe questions to assure full coverage of concept domains.
Transcripts were coded using Atlas.ti and summarized by distinct concepts. Inter-
view guide notations were used to tag each concept offered by spontaneous versus
probed report. RESULTS: Forty-three patient interviews were conducted (mean
age: 48.613.0, 53.5% female, 74.4% -White/Caucasian). Mean (SD) pain NRS score
was 6.7(1.3). Spontaneously reported symptoms included: Numbness (51.2% of sub-
jects), Burning (39.5%), and Pain that was Shooting (37.2%), Stabbing (37.2%), and
Sharp (37.2%). The low back pain symptoms reported most often in response to
probes included Stiffness (55.8% of subjects), Excruciating Pain (41.9%), Pressure
(39.5%), Cramping (32.6%), and Pins and Needles (30.2%). Spontaneously reported
impacts included interference with: Walking (65.1%), Sitting (62.8%), Exercise
(58.1%), Leisure Activities (58.1%), Sleeping (55.8%), Household Chores (53.5%), and
Emotional Impacts (48.8%). Impacts reported most often in response to probes
included Low Energy because of pain (67.4%), Productivity (65.1%), Financial Impact
(46.5%), Driving (39.5%), and Relationships (37.2%). CONCLUSIONS: Given the vari-
ety of symptoms and impacts described by patients as part of their cLBP experi-
ence, those reported spontaneously may be more relevant to patients compared to
those reported upon probes. Characterizing patient reported concepts by sponta-
neous and probed may be useful in increasing the overall sensitivity of the patient
reported outcome assessment tool to detect change.
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OBJECTIVES: Evaluate the reliability and validity of the LIT, a 10-item PRO assess-
ment of the impact of SLE on the patient’s life. Additionally, the acceptability and
feasibility of LIT from the patient’s and physician’s perspectives was assessed.
METHODS: Baseline data were collected on 325 SLE patients during a clinic visit.
Patients completed the LIT, SF-36v2, LupusQoL, and PHQ-9. Both patients and phy-
sicians completed a questionnaire on the feasibility/acceptability of LIT. Patients
completed the LIT 7-14 days following baseline to assess test-retest reliability.
Physicians completed disease activity assessments (SELENA-SLEDAI, BILAG, and
SLICC/ACR Damage Index), a physician’s global assessment (PGA) and patient’s
recent flare status. Reliability was evaluated using internal consistency methods
(Cronbach’s alpha) and test-retest methods (intra-class correlation). Convergent
validity was evaluated by correlating LIT scores with scale scores from the SF-36v2,
LupusQoL, and PHQ-9. Construct validity was evaluated by comparing mean LIT
scores across patients that differed in PGA ratings and presence/absence of a recent
flare. ANOVA and Student’s t-tests were used to test mean differences in LIT scores
across patient groups. It was hypothesized that LIT scores would be lower among
patients with lower PGA ratings and no recent flare. RESULTS: Internal consistency
and test–retest reliabilities of LIT were 0.90 and 0.88, respectively. Convergent va-
lidity correlations ranged from -0.63 to -0.75 with SF-36v2 scales, from -0.42 to -0.75
with LupusQoL scales, and 0.75 with the PHQ-9. Mean LIT scores differed as hy-
pothesized across patients with different PGA ratings (F5.8, df2, p0.004). Mean
LIT scores differed between patients with and without a recent SLE Flare (t2.11,
p0.038). The majority (70%) of both patients and physicians found LIT to be
acceptable and feasible to administer in a clinic setting. CONCLUSIONS: The LIT is
a reliable and valid instrument for assessing the impact of SLE on patient’s func-
tioning and well-being.
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OBJECTIVES: Scarce data is available on the economic burden associated with
haemophilia B (HB). The aim of this study was to evaluate in a representative
French HB population the impact on health-related quality of life (HRQOL) and to
estimate the costs associated with its management. METHODS: EQOFIX is a pro-
spective cohort study in patients with moderate and severe HB with one year
follow-up. Data collected included: patients’ demographic and clinical character-
istics, severity status, therapeutical approach, FIX consumption and all other re-
sources used. Two types of HRQOL were used: generic (Kidscreen for children and
SF-36 for adults) and specific (QUAL-HEMO, specific to haemophilia patients). The
French national health insurance perspective was considered to estimate the av-
erage annual cost using official cost database. RESULTS:A total of 155 patients had
been included by 27 centres, representing a coverage rate of 25% of the French
global population suffering from severe and moderate HB: 104 adults (74 severe and
30 moderate) and 51 children (40 severe and 11 moderate). 30.4% of patients re-
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